Holen Sie sich die Stockscreener-App
1.58
16.49%
-0.30
Schlusskurs vom Vortag:
$1.88
Offen:
$1.63
24-Stunden-Volumen:
2.70M
Relative Volume:
0.43
Marktkapitalisierung:
$8.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+61.92%
1M Leistung:
+118.06%
6M Leistung:
-99.56%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.49
$1.71
1-Wochen-Bereich:
$0.85
$1.89
52-Wochen-Spanne:
$0.55
$1,200.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Vergleichen Sie PLRZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
1.56 | 7.73M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.42 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.29 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.27 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
582.48 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.70 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
Is Polyrizon Ltd. a good long term investmentBreakthrough financial growth - Autocar Professional
Polyrizon Ltd. Stock Analysis and ForecastExceptional growth trajectory - jammulinksnews.com
Polyrizon Stock Soars 37.93% on Nasal Allergy Breakthrough - AInvest
Why Did Polyrizon Stock Soar 26.21%? - AInvest
Polyrizon Skyrockets 66% Intraday—Can This Nasal Allergy Breakthrough Reshape Biotech? - AInvest
Polyrizon Skyrockets 61.93% Intraday, Is This the Dawn of a Biotech Breakthrough? - AInvest
Polyrizon stock soars after promising nasal allergy blocker test results - Investing.com
Polyrizon Ltd. Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study - MarketScreener
Polyrizon Achieves Breakthrough in Allergy Blocker Study - TipRanks
Polyrizon’s nasal allergy blocker shows promising deposition results - Investing.com Australia
Polyrizon's Nasal Barrier: A Disruptive Leap in Allergy Therapeutics? - AInvest
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study - The Manila Times
Breakthrough: New Allergy Blocker Shows 60% Success Rate in Nasal Delivery StudyMajor Step for $210M Market - Stock Titan
What drives Polyrizon Ltd. stock priceDynamic investment growth - jammulinksnews.com
What analysts say about Polyrizon Ltd. stockDynamic capital growth - jammulinksnews.com
Polyrizon retains Nasdaq listing following hearings panel - MSN
Biotech Alert: Searches spiking for these stocks today - TipRanks
Best Biotech Stocks To Research – July 15th - Defense World
Polyrizon Plunges 11.06% Amid Market Challenges - AInvest
Polyrizon Stock Slides After Hours After 52% Surge On Tuesday: Why It Moved - Benzinga
Polyrizon Retains Nasdaq Listing Following Hearings Panel - 富途牛牛
Why Polyrizon Ltd. stock attracts strong analyst attentionFree Access to Stock Community - Newser
How Polyrizon Ltd. stock performs during market volatilitySmart Trading With Safety Margin - Newser
What makes Polyrizon Ltd. stock price move sharplyFree High-Accuracy Stock Picks - Newser
Polyrizon Ignites 65% Surge—What’s Driving the Unstoppable Rally? - AInvest
Polyrizon secures continued Nasdaq listing after panel hearing By Investing.com - Investing.com Canada
Polyrizon secures continued Nasdaq listing after panel hearing - Investing.com
Polyrizon Ltd. Secures Continued Nasdaq Listing Following Compliance Plan Implementation - Nasdaq
Polyrizon Wins Crucial Nasdaq Appeal: Inside the $15.7M Biotech's Path to Compliance - Stock Titan
Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest - MSN
Polyrizon Ltd. Announces Board Changes and Confirms Independent Directors - The Globe and Mail
Polyrizon director Omer Srugo resigns; board affirms independent members - Investing.com
Polyrizon director Omer Srugo resigns; board affirms independent members By Investing.com - Investing.com UK
Polyrizon Ltd Inc. (PLRZ) Price Performance: How to Use Technical Analysis to Make Trading Decisions - investchronicle.com
Polyrizon Plunges 8.5% Amid Reverse Split, Promising Drug Delivery Results - AInvest
Polyrizon’s nasal drug delivery system shows promising results By Investing.com - Investing.com South Africa
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics - MarketScreener
Polyrizon’s nasal drug delivery system shows promising results - Investing.com Australia
Polyrizon Announces Promising Preclinical Results for CNS Therapeutics - TipRanks
Finanzdaten der Polyrizon Ltd-Aktie (PLRZ)
Es liegen keine Finanzdaten für Polyrizon Ltd (PLRZ) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.89%
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):